HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more
feasible with better regimens to prevent graft versus host disease (GVHD) like post
transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been
shown to inhibit dendritic cells maturation and function and possesses a number of other
favorable immunomodulatory effect that can prevent GVHD and help enhance immune
reconstitution. this study is to assess the engraftment rate in patients with hematologic
malignancies who need allogeneic stem cell transplant but do not have a suitable matched
related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical
allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and
bortezomib